NBOMe-LAD
Pharmaceutical compound
From Wikipedia, the free encyclopedia
NBOMe-LAD, also known as LSD-NBOMe, is a serotonin receptor modulator and putative psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[1] It is the N-(2-methoxybenzyl) (NBOMe) derivative of LSD.[1]
- None
 | |
| Clinical data | |
|---|---|
| Other names | LAD-NBOMe; LSD-NBOMe; NBOMe-LSD; 6-(2-Methoxybenzyl)-LAD; WO 2022/226408 Example 10; N,N-Diethyl-6-[(2-methoxyphenyl)methyl]-9,10-didehydroergoline-8β-carboxamide |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C27H31N3O2 |
| Molar mass | 429.564 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pharmacology
Pharmacodynamics
NBOMe-LAD is known to act as an agonist of the serotonin 5-HT2A receptor and to interact with other receptors, but shows dramatically reduced potency compared to LSD in vitro.[1] At the serotonin 5-HT2A receptor, it had 37-fold lower affinity, 148-fold lower activational potency in terms of calcium release, and around half the maximal efficacy in terms of calcium release relative to LSD.[1] On the other hand, NBOMe-LAD had only about 4-fold lower potency in terms of β-arrestin recruitment along with similar activational efficacy for this pathway relative to LSD.[1]
NBOMe-LAD produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, but with greatly reduced potency and maximal efficacy relative to PRO-LAD and analogues.[1] Its ED50 for inducing the head-twitch response was 13-fold lower than that of PRO-LAD and its maximal effect was about one-third that of PRO-LAD.[1] However, the most efficacious dose of NBOMe-LAD was 3.2 mg/kg whereas that of PRO-LAD was 1 mg/kg.[1]
Pharmacokinetics
NBOMe-LAD showed much faster metabolism than LSD in human and rat liver microsomes in vitro.[1]
History
NBOMe-LAD was first described in the literature by 2022.[1] It was described in a patent by Andrew Kruegel and Gilgamesh Pharmaceuticals.[1] Various other NBOMe-type analogues of LSD and related compounds were also described.[1]